News
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
12 Apr 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
12 Apr 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
12 Apr 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Nurix Therapeutics Prices Upsized $175M Public Offering Of 10,166,667 Common Shares At $15/Share
12 Apr 24
News
12 Health Care Stocks Moving In Thursday's After-Market Session
11 Apr 24
Movers
Nurix Therapeutics Commences Public Offering Of $125M Of Its Common Stock And, In Lieu Of Common Stock, In Case Of Certain Investors, Pre-funded Warrants To Purchase Shares
11 Apr 24
News, Offerings
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
11 Apr 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $23
11 Apr 24
News, Price Target, Analyst Ratings
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
11 Apr 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $25
11 Apr 24
News, Price Target, Analyst Ratings
Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price Target
11 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Nurix Therapeutics Q1 GAAP EPS $(0.76) Beats $(0.80) Estimate, Sales $16.59M Miss $16.64M Estimate
10 Apr 24
Earnings, News
Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price Target
10 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Nurix Therapeutics Reports First Clinical Evidence Of CNS Activity Of NX-5948, Orally Available, BTK Degrader In Development For B Cell Malignancies
9 Apr 24
Biotech, News, General
12 Health Care Stocks Moving In Tuesday's Intraday Session
9 Apr 24
Movers
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
9 Apr 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Nurix Therapeutics Extends Ongoing Research Program With Sanofi For STAT6; Anticipates Nominating A Clinical Candidate Within The First Year Of Extension
9 Apr 24
News
Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price Target
9 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Critical Insights From Nurix Therapeutics Analyst Ratings: What You Need To Know
2 Apr 24
Analyst Ratings
Needham Maintains Buy on Nurix Therapeutics, Maintains $31 Price Target
2 Apr 24
News, Price Target, Analyst Ratings
Press releases
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
16 Apr 24
Health Care, Press Releases, General
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
11 Apr 24
News, Financing, Press Releases
Nurix Therapeutics Announces Proposed Public Offering
11 Apr 24
News, Financing, Press Releases
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
9 Apr 24
Health Care, Press Releases
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
2 Apr 24
Health Care, Press Releases
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
25 Mar 24
Analyst Ratings, Press Releases
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
20 Mar 24
News, Health Care, Press Releases
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
11 Mar 24
Press Releases
Nurix Therapeutics to Participate in Upcoming Investor Conferences
6 Mar 24
News, Press Releases
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
15 Feb 24
Earnings, Press Releases
Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader
1 Feb 24
Health Care, Analyst Ratings, Press Releases